JP6082174B2 - 免疫調節組成物及びその使用方法 - Google Patents

免疫調節組成物及びその使用方法 Download PDF

Info

Publication number
JP6082174B2
JP6082174B2 JP2009536266A JP2009536266A JP6082174B2 JP 6082174 B2 JP6082174 B2 JP 6082174B2 JP 2009536266 A JP2009536266 A JP 2009536266A JP 2009536266 A JP2009536266 A JP 2009536266A JP 6082174 B2 JP6082174 B2 JP 6082174B2
Authority
JP
Japan
Prior art keywords
glucan
composition
antibody
certain embodiments
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009536266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527906A (ja
JP2010527906A5 (enExample
Inventor
ベジャー アノ、イファット ルビン
ベジャー アノ、イファット ルビン
フィンク、ジェラード・アール．
アベイホン、クラウディア
コハネ、ダニエル・エス．
フラー、ジェイソン
ランガー、ロバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Original Assignee
Boston University
Massachusetts Institute of Technology
Whitehead Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, Massachusetts Institute of Technology, Whitehead Institute for Biomedical Research filed Critical Boston University
Publication of JP2010527906A publication Critical patent/JP2010527906A/ja
Publication of JP2010527906A5 publication Critical patent/JP2010527906A5/ja
Application granted granted Critical
Publication of JP6082174B2 publication Critical patent/JP6082174B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/09—Lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
JP2009536266A 2006-11-06 2007-11-06 免疫調節組成物及びその使用方法 Expired - Fee Related JP6082174B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US85683406P 2006-11-06 2006-11-06
US60/856,834 2006-11-06
US88038407P 2007-01-16 2007-01-16
US60/880,384 2007-01-16
US92975507P 2007-07-11 2007-07-11
US60/929,755 2007-07-11
PCT/US2007/023307 WO2008057501A2 (en) 2006-11-06 2007-11-06 Immunomodulating compositions and methods of use thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014022905A Division JP2014129366A (ja) 2006-11-06 2014-02-08 免疫調節組成物及びその使用方法
JP2016112724A Division JP2016188230A (ja) 2006-11-06 2016-06-06 免疫調節組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2010527906A JP2010527906A (ja) 2010-08-19
JP2010527906A5 JP2010527906A5 (enExample) 2011-04-14
JP6082174B2 true JP6082174B2 (ja) 2017-02-15

Family

ID=39365102

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2009536266A Expired - Fee Related JP6082174B2 (ja) 2006-11-06 2007-11-06 免疫調節組成物及びその使用方法
JP2014022905A Pending JP2014129366A (ja) 2006-11-06 2014-02-08 免疫調節組成物及びその使用方法
JP2016112724A Pending JP2016188230A (ja) 2006-11-06 2016-06-06 免疫調節組成物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014022905A Pending JP2014129366A (ja) 2006-11-06 2014-02-08 免疫調節組成物及びその使用方法
JP2016112724A Pending JP2016188230A (ja) 2006-11-06 2016-06-06 免疫調節組成物及びその使用方法

Country Status (5)

Country Link
US (1) US8580253B2 (enExample)
EP (1) EP2066294B9 (enExample)
JP (3) JP6082174B2 (enExample)
ES (1) ES2397186T3 (enExample)
WO (1) WO2008057501A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
US9457047B2 (en) * 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
AU2011289579B2 (en) 2010-08-10 2016-11-17 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
JP2012205656A (ja) * 2011-03-29 2012-10-25 Kyocera Medical Corp 生体インプラント用被覆材料、およびインプラント
WO2012139089A2 (en) 2011-04-08 2012-10-11 The General Hospital Corporation Fungal-derived carbohydrate-conjugated scaffold
WO2012154818A1 (en) * 2011-05-09 2012-11-15 Biothera, Inc. B-glucan compounds, compositions, and methods
US10092657B2 (en) * 2011-06-03 2018-10-09 Biothera, Inc. Opsonized β-glucan preparations and methods
ES2887367T3 (es) * 2013-10-09 2021-12-22 Toray Industries Inmunopotenciador
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
LT3107563T (lt) 2014-02-21 2021-07-12 Ecole Polytechnique Fédérale De Lausanne (Epfl) Epfl-Tto Gliko-nukreipiantys terapiniai agenai
WO2015172040A2 (en) * 2014-05-08 2015-11-12 Immunexcite, Inc. IMMUNOMODULATING β-1,6-D-GLUCANS
US9480656B1 (en) 2015-09-28 2016-11-01 King Saud University Method of preparing rosemary nanoparticles and encapsulated rosemary nanoparticles
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
JP7534312B2 (ja) 2019-02-15 2024-08-14 ザ クリーブランド クリニック ファウンデーション ワクチンアジュバント及び製剤
WO2020236626A1 (en) * 2019-05-17 2020-11-26 Herzlinger George A Methods and systems for treating microbial disease
EP3858362A1 (en) * 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan for use in enhancement of anti-tumor immunity in remission
WO2021152497A1 (en) * 2020-01-29 2021-08-05 Pleuran, S.R.O. Beta-glucan for use in modulation of an immune response in a remission

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4590181A (en) * 1982-12-20 1986-05-20 Board Of Regents Of The University Of Nebraska Synthetic immunoregulators and methods of use and preparation
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4992540A (en) * 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
ATE153856T1 (de) * 1989-09-08 1997-06-15 Alpha Beta Technology Zusammensetzung zur stimulierung des immunsystems
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0640348A1 (en) 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
NO300692B1 (no) * 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US6048551A (en) * 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
US6046323A (en) * 1997-07-29 2000-04-04 The Collaborative Group, Ltd. Conformations of PPG-glucan
US6468519B1 (en) * 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
AU6261999A (en) * 1998-09-25 2000-04-17 Collaborative Group, Ltd., The Very high molecular weight beta-glucans
US6328988B1 (en) * 1999-04-23 2001-12-11 Rutgers, The State University Of New Jersey Hyperbranched polymeric micelles for encapsulation and delivery of hydrophobic molecules
US7011845B2 (en) * 2000-05-09 2006-03-14 Mcp Hahnemann University β-glucans encapsulated in liposomes
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20040127458A1 (en) * 2000-11-06 2004-07-01 Hunter Kenneth W. Beta-glucan containing compositions, methods for manufacturing beta-glucans, and for manufacturing and using beta-glucans and conjugates thereof as vaccine adjuvants
US6476003B1 (en) * 2000-11-06 2002-11-05 Immusonic, Inc. Method for preparing small particle size glucan in a dry material
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20050191361A1 (en) * 2001-08-03 2005-09-01 Powederject Research Ltd. Hydrogel particle formation
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
WO2004021994A2 (en) * 2002-09-04 2004-03-18 Biopolymer Engineering, Inc. Cancer therapy using whole glucan particles and antibodies
US7060299B2 (en) * 2002-12-31 2006-06-13 Battelle Memorial Institute Biodegradable microparticles that stabilize and control the release of proteins
US8048432B2 (en) * 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
WO2007033315A1 (en) * 2005-09-14 2007-03-22 Whitehead Institute For Biomedical Research Drug induced exposure of the fungal pro-inflammatory molecule beta-glucan
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
WO2009134891A2 (en) 2008-04-29 2009-11-05 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof

Also Published As

Publication number Publication date
EP2066294A4 (en) 2010-02-24
EP2066294A2 (en) 2009-06-10
JP2010527906A (ja) 2010-08-19
JP2014129366A (ja) 2014-07-10
WO2008057501A2 (en) 2008-05-15
JP2016188230A (ja) 2016-11-04
EP2066294B1 (en) 2012-10-10
US20110045049A1 (en) 2011-02-24
WO2008057501A9 (en) 2008-07-10
US8580253B2 (en) 2013-11-12
WO2008057501A3 (en) 2008-10-02
ES2397186T3 (es) 2013-03-05
WO2008057501A8 (en) 2008-08-21
EP2066294B9 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
JP6082174B2 (ja) 免疫調節組成物及びその使用方法
US9457047B2 (en) Immunomodulating compositions and methods of use thereof
JP5959589B2 (ja) 免疫調節組成物およびその使用方法
US20220218837A1 (en) Drug conjugate
US10195144B2 (en) Methods of treating inflammatory and autoimmune diseases and disorders
TW200911274A (en) Alpha-galatosyl ceramide analogs and their use as immunotherapies
JP2009527566A (ja) 免疫治療のためのナノ粒子
ES2869181T3 (es) Métodos y preparaciones de beta-glucano opsonizado
JP2019504895A (ja) スギ花粉エピトープを封入するｔｉｍｐ（組織性メタロプロテアーゼ阻害因子）
US12121573B2 (en) Methods and agents including STING agonist to treat tumor
WO2019160780A1 (en) Methods and agents to treat tumor cells and cancer
AU2013203785B2 (en) Immunomodulating compositions and methods of use thereof
US20170252365A1 (en) Immunomodulating compositions and methods of use thereof
JP2004528321A (ja) ステロールおよびサポニンを含むポリヌクレオチド結合複合体
CA3225745A1 (en) Targeted glycosaminoglycan-particles and methods of use
Ahmed Assembly and characterization of a cell-particle hybrid system as a potential cancer vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110104

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130521

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140310

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20140310

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20140313

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140417

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170120

R150 Certificate of patent or registration of utility model

Ref document number: 6082174

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees